Metraipolis › archive › dc_ca470e9339b4

Case Report: Efgartigimod demonstrates significant clinical efficacy in double seropositive myasthenia gravis: a case report of a rare variant and analysis of… — Europe PMC PMID:41159035

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41159035
DOI
10.3389/fimmu.2025.1610738
License (as archived)
solo-consultazione
Archived
2026-11-09T09:10:50.954Z
SHA-256 of the archived text
b27d03ec0c01d8093d6e3f92bcca1418b1e4cc517ec84d840b5775e2c1d9c99c
Stable URL of this page
https://metraipolis.com/documento/dc_ca470e9339b4

How to cite

Case Report: Efgartigimod demonstrates significant clinical efficacy in double seropositive myasthenia gravis: a case report of a rare variant and analysis of… — Europe PMC PMID:41159035 — Europe PMC (en), https://europepmc.org/article/MED/41159035 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ca470e9339b4 (Metraipolis archive dc_ca470e9339b4, sha256 b27d03ec0c01d8093d6e3f92bcca1418b1e4cc517ec84d840b5775e2c1d9c99c)
BibTeX
@misc{dcca470e9339b4,
  title = {Case Report: Efgartigimod demonstrates significant clinical efficacy in double seropositive myasthenia gravis: a case report of a rare variant and analysis of… — Europe PMC PMID:41159035},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41159035},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ca470e9339b4; sha256 b27d03ec0c01d8093d6e3f92bcca1418b1e4cc517ec84d840b5775e2c1d9c99c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41159035. Agents can read the archived copy with the MCP tool read_document.